Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disease affecting the kidney's filtering system (glomeruli) and resulting in serious scarring and end stage renal disease. For instance, according to the article in Clinical Journal of American Society of Nephrology, 2017, FSGS incidence rates are often higher in men, an estimated 1.5-fold higher as compared to women. FSGS is characterized by symptoms such as edema, proteinuria, weight gain, increased cholesterol, and proteins in blood.
Focal Segmental Glomerulosclerosis Market – Drivers
As there is no drug approved for the treatment of FSGS yet. Thus, limited treatment therapy and government funding for research on rare diseases are expected to drive growth of the FSGS market. For instance, in 2015, the U.S. Food and Drug Administration (FDA) and European Commission both granted Sparsentan, as orphan drug designation for the treatment of FSGS. This Sparsentan is a novel drug candidate with dual mechanism of action combines angiotensin receptor blockade with endothelin receptor blockade and is currently being evaluated in a Phase III trial, which expected to complete in December 2022.
Increasing research and development for FSGS drugs by various manufacturers is also fueling growth of the FSGS market. For instance, Pfizer Inc., is undergoing clinical trial for the evaluation of its drug, PF-06730512 in adults with primary focal segmental glomerulosclerosis. This drug is currently in Phase II study and is expected to complete in June 2021.
Moreover, government investments into the rare disease treatment is expected to drive the growth of market. For instance, according to an annual data report from the U.S. Renal Data System 2017, Medicare invested around US$ 34 billion for people on dialysis with chronic kidney disease.
Focal Segmental Glomerulosclerosis Market – Restraint
Lack of awareness among population regarding this disease and high cost of dialysis therapy may restrict growth of this market to some extent. For instance, according to an article published in University of Michigan 2017, awareness among patients with FSGS is considerably low when the patients are in primary stage of FSGS, which is hampering growth of the FSGS market.
Focal Segmental Glomerulosclerosis Market – Regional Analysis
On the basis of region, the global focal segmental glomerulosclerosis market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to dominate the FSGS market due to high prevalence of FSGS along with chronic kidney diseases. For instance, According to an annual data report by the U.S. Renal Data System 2017, the overall burden of kidney disease, kidney failure with dialysis, and kidney transplantation is highest in U.S., thus driving the growth of the focal segmental glomerulosclerosis market.
Asia Pacific region is expected to witness significant growth in market due to collaboration agreements and partnerships among various players. For instance, Oraxion Therapeutics, Inc., a subsidiary of Indian company Aten Porus, is undergoing preclinical and efficacy study of the drug, ORX-301, which can be used in the treatment of FSGS. In February 2018, Oraxion Therapeutics, Inc., entered into an Option Agreement with the U.S-based Biopharmaceutical Company and under this agreement, U.S. based company gets exclusive rights for further clinical studies and license of this drug in the U.S.
The key players operating in the focal segmental glomerulosclerosis (FSGS) market include GlaxoSmithKline plc., Novartis AG, Variant Pharmaceuticals, Inc., ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., Pfizer, Inc., AstraZeneca plc., Sanofi S.A, and Teva Pharmaceutical Industries Ltd.
Focal Segmental Glomerulosclerosis Market – Taxonomy
By Disease Type
By Distribution channels
Joining thousands of companies around the world committed to making the Excellent Business Solutions.View All Our Clients